

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUSCATPE

Page 1 of 2

DOCTOR'S ORDERS Ht	cm	Wt	kg	BSA	m²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form					
DATE: To be given:			(Cycle #:	
Date of Previous Cycle:					
□ Delay treatment week(s)□ CBC & Diff, Platelets day of treatment					
May proceed with doses as written on Day 1 if within 96 hours ANC greater than or equal to 1.5 x 10°/L, Platelets greater than or equal to 100 x 10°/L, Creatinine Clearance greater than or equal to 60 mL/minute (if using CISplatin), ALT less than or equal to 3 times the upper limit of normal, bilirubin less than or equal to 1.5 times the upper limit of normal, creatinine less than or equal to 1.5 times the upper limit of normal and less than or equal to 1.5 times baseline. Dose modification for: Hematology Other Toxicity Proceed with treatment based on blood work from					
PREMEDICATIONS: Patient to take own supply. RN/P	harma	cist to co	nfirm		·
Cycles 1 to 4: ondansetron 8 mg PO 30 to 60 minutes prior to treatment on Days 1 to 3 dexamethasone					
For prior atezolizumab infusion reaction: diphenhydrAMINE 50 mg PO 30 minutes prior to treatment acetaminophen 325 to 975 mg PO 30 minutes prior to treatment hydrocortisone 25 mg IV 30 minutes prior to treatment Other:					
Have Hypersensitivity Reaction Tray and Protocol Available					
CHEMOTHERAPY:					
☐ CYCLE 1:					
atezolizumab 1200 mg IV in 250 mL NS over 1 hour Day 1 only					
CISplatin 25 mg/m²/day x BSA = mg Dose Modification: % = mg/m² x BSA = mg IV in 100 to 250 mL NS over 30 minutes x 3 days OR					
CARBOplatin AUC 5 x (GFR + 25) = mg IV in 100 to 250 mL NS over 30 minutes Day 1 only					
etoposide 100 mg/m²/day x BSA = mg Dose Modification: mg/m² x BSA = mg IV in 250 to 1000 mL (non-DEHP bag) NS over 45 minutes to 1 hour 30 minutes x 3 days (use non-DEHP tubing with 0.2 micron in-line filter)					
SEE PAGE 2 FOR CHEMOTHERAPY CYCLES 2 ONWARDS					
DOCTOR'S SIGNATURE:					SIGNATURE: UC:
DOCTOR'S ORDERS					



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUSCATPE

Page 2 of 2

DATE:				
CHEMOTHERAPY: (continued) ***SEE PAGE 1 FOR CHEMOTHERAPY CYCLE 1***				
CYCLES 2 to 4: atezolizumab 1200 mg IV in 250 mL NS over 30 minutes Day 1 only CISplatin 25 mg/m²/day x BSA = mg Dose Modification: % = mg/m² x BSA = mg IV in 100 to 250 mL NS over 30 minutes x 3 days OR CARBOplatin AUC 5 x (GFR + 25) = mg IV in 100 to 250 mL NS over 30 minutes Day 1 only etoposide 100 mg/m²/day x BSA = mg Dose Modification: mg/m² x BSA = mg IV in 250 to 1000 mL (non-DEHP bag) NS over 45 minutes to 1 hour 30 minutes x 3 days (use non-DEHP tubing with 0.2 micron in-line filter)				
OR ☐ CYCLE 5 onwards: atezolizumab 1200 mg IV in 250 mL NS over 30 minutes				
STANDING ORDER FOR ETOPOSIDE TOXICITY: hydrocortisone 100 mg IV prn / diphenhydrAMINE 50 mg IV prn				
RETURN APPOINTMENT ORDERS				
Return in three weeks for Doctor and Cycle Book chemo x 3 days for cycles 1 to 4. Return in three weeks for Doctor and Cycle 5. Book chemo on day 1 for cycle 5 onwards. Last Cycle. Return in week(s).				
CBC and diff, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH prior to each cycle				
If clinically indicated:				
DOCTOR'S SIGNATURE:	SIGNATURE: UC:			